Seeking Alpha

Prothena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In Place

Prothena Corporation plc (PRTA) just the other week announced data from its phase 3 AFFIRM-AL clinical trial using birtamimab for the treatment of patients with AL amyloidosis. The really bad news ...